Placebo-Controlled, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-933043
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2014
At a glance
- Drugs BMS 933043 (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 26 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Jan 2014 Planned number of patients changed from 86 to 136 according to ClinicalTrials.gov record.
- 09 Jan 2014 Planned End Date changed from 1 Mar 2014 to 1 Dec 2013 according to ClinicalTrials.gov record.